Brief CorrespondenceExpression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer
References (10)
- et al.
Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer
Eur Urol
(2018) - et al.
Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer
Eur Urol
(2017) - et al.
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
Ann Oncol
(2009) - et al.
AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: association with treatment-specific outcome under abiraterone and enzalutamide
Eur Urol
(2017) - et al.
AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate
J Urol
(2017)
Cited by (35)
Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer
2021, Urologic Oncology: Seminars and Original InvestigationsUpregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis
2021, GeneCitation Excerpt :In addition, Liu et al. (2016) explained that by eliminating the circulating tumor cell (CTC) selection process, they shortened the application time and increased the sensitivity of the test, thereby enabling more patients to benefit from these tests. However, To et al. (2018) suggested that the expression states of AR variant 7 or 9 in whole blood cannot predict response to agents targeting the androgen pathway in mCRPC. They also stated that progression-free survival rate did not differ significantly between variant positive and variant negative patients.
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
2021, European Urology FocusCitation Excerpt :The TMPRSS2:ERG fusion transcript was included given its demonstrated value as a treatment biomarker [16]. Finally, we included our previously optimised, highly sensitive, and specific whole-blood assay for AR-V7 and AR-V9 [1]. Peripheral blood (2.5 ml) was collected in a PAXgene RNA blood tube (Qiagen, Hilden, Germany) and stored at −80 °C until batch sample processing.
Current strategies for targeting the activity of androgen receptor variants
2019, Asian Journal of UrologyCitation Excerpt :Furthermore, when Efstathiou et al. [41] analyzed AR-V7 protein levels in 60 patients with bone metastatic CRPC before and 8 weeks after enzalutamide treatment, AR-V7 expression was found to be associated with primary resistance to enzalutamide. However, To et al. [22] were unable to correlate baseline AR-V7 or AR-V9 in whole blood to PSA response rate or PSA progression-free survival. Overall, the varying results from these studies suggest that the potential of AR-V7 as a predictive biomarker is still ambiguous and more study in this area is needed.
- †
These authors contributed equally to this work.